Dr. Uesaka on Gemcitabine vs S-1 in Pancreatic Cancer
Katsuhiko Uesaka, MD, PhD, from the Shizuoka Cancer Center Hospital in Japan, discusses the JASPAC-01 study that compared gemcitabine to S-1 in Asian patients with resected pancreatic cancer.
Katsuhiko Uesaka, MD, PhD, medical deputy director at Shizuoka Cancer Center Hospital in Japan, discusses the JASPAC-01 study that compared gemcitabine to S-1 in Asian patients with resected pancreatic cancer.
In the phase III trial, 378 Japanese patients with resected pancreatic cancer were randomized to receive adjuvant treatment with the chemotherapy S-1 or gemcitabine. The goal of the trial was to prove that S-1 was noninferior to gemcitabine, in this patient population.
At the first interim analysis, the risk of death was 44% lower in the S-1 arm versus the gemcitabine group (HR = 0.56; P <.0001). The 2-year overall survival rate was 70% with S-1 versus 53% with gemcitabine.
Uesaka notes that this data shows that S-1 is significantly noninferior and superior to gemcitabine as an adjuvant treatment for pancreatic cancer.
<<<
